MYC copy number and mRNA expression in chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chornobyl NPP accident
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-1.14214Keywords:
8q24.1, chronic lymphocytic leukemia, gene copy number, MYC geneAbstract
Summary. Some clinical and biological features indicating an unfavorable course of the disease were found in ionizing radiation (IR) — related chronic lymphocytic leukemia (CLL) patients. The MYC proto-oncogene is considered to contribute to CLL pathogenesis. Increased MYC copy number is associated with poor prognosis in CLL. Aim: To investigate the frequency of MYC gene copy number amplification in IR-exposed CLL patients and relate the findings to the MYC mRNA levels, the presence of unfavourable prognosis mutations (TP53, SF3B1, NOTCH1), and patient's outcome. Materials and Methods: The analysis of MYC copy number was carried out by real-time quantitative polymerase chain reaction (PCR) in 70 IR-exposed CLL patients. The MYC mRNA expression was measured by real-time quantitative reverse transcription PCR. Results: Increased MYC gene copy number was present in 5.7% of cases. There was a statistically significant association between increased MYC copy number and increased MYC mRNA (p < 0.014). Additionally, somatic deletion in MYC locus was found in one patient. Most of patients (80%) with detected MYC aberrations were previously untreated, suggesting that these lesions might occur early in the course of the disease. The MYC aberrations were found mutually exclusive with high risk TP53 and SF3B1 mutations, while one case was identified, where MYC amplification and NOTCH1 mutation coincided simultaneously. Regarding clinical outcome, the MYC aberrations were associated with a shorter time to first treatment (3 vs 25 months, p = 0.008) as well as reduced overall survival (60 vs 139 months). Conclusion: Our data suggest that MYC aberrations might be an early event in IR-related CLL and contribute to aggressive disease development in the absence of high risk TP53 and SF3B1 mutations.
References
Montillo M, Hamblin T, Hallek M, et al. Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies. Haematologica 2005; 90: 391–9.
Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526: 525–30.
Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008; 8: 976–90.
Knoepfler PS. Myc goes global: New tricks for an old oncogene. Cancer Res 2007; 67: 5061–3.
Levens D. How the c-myc promoter works and why it sometimes does not. J Natl Cancer Inst Monogr 2008; 39: 41–3.
Dang CV, O’Donnell KA, Zeller KI, et al. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253–64.
Dang CV. MYC on the path to cancer. Cell 2012; 149: 22–35.
Herrick DJ, Ross J. The half-life of c-myc mRNA in growing and serum-stimulated cells: Influence of the coding and 3’ untranslated regions and role of ribosome translocation. Mol Cell Biol 1994; 14: 2119–28.
Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: Differential expression in neoplastic cells. Mol Cell Biol 1984; 4: 2486–97.
Nguywen L, Papenhausen P, Shao H. The role of c-MYC in B cell lymphomas: diagnostic and molecular aspects. Genes (Basel) 2017; 8: 116.
Brown JR, Hanna M, Tesar B, et al. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18: 3791–802.
Caraballo JM, Acosta JC, Cortés MA, et al. High p27 protein levels in chronic lymphocytic leukemia are associated to low Myc and Skp2 expression, confer resistance to apoptosis and antagonize Myc effects on cell cycle. Oncotarget 2014; 5: 4694–708.
Rossi D. MYC addiction in chronic lymphocytic leukemia. Leuk Lymphoma 2013; 54: 905–6.
Edelmann J, Holzmann K, Tausch E, et al. Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1 regulated transcription. Haematologica 2019. pii: haematol.2019.217307 [Epub ahead of print].
Zhang W, Kater AP, Widhopf GF, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2010; 107: 18956–60.
Abramenko I, Bilous N, Chumak A, et al. Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident — with focus on immunoglobulin heavy chain gene analysis. Leuk Res 2008; 32: 535–45.
Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.
Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–34.
Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–7.
Bilous NI, Abramenko IV, Chumak AA, et al. The spectrum of TP53, SF3B1, and NOTCH1 mutations in chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chornobyl NPP accident. Probl Radiac Med Radiobiol 2018; 23: 283–301.
Chen H, Liu W, Roberts W, et al. 8q24 allelic imbalance and MYC gene copy number in primary prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 238–43.
Buscarlet M, Krasteva V, Ho L, et al. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood 2014; 23: 1720–8.
Weaver S, Dube S, Mir A, et al. Taking qPCR to a higher level: Analysis of CNV reveals the power of high throughput qPCR to enhance quantitative resolution. Methods 2010; 50: 271–6.
Kindich R, Florl AR, Jung V, et al. Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. Clin Chem 2005; 51: 649–52.
Bilous N, Abramenko I, Chumak A, et al. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia. Exp Oncol 2019; 41: 39–45.
Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‚real-time‘ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) — a Europe against cancer program. Leukemia 2003; 17: 2474–86.
López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun 2019; 10: 1459.
Amati B. Myc degradation: dancing with ubiquitin ligases. Proc Natl Acad Sci USA 2004; 101: 8843–4.
Stasik CJ, Nitta H, Zhang W, et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 2010; 95: 597–603.
Korz C, Pscherer A, Benner A, et al. Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. Blood 2002; 99: 4554–61.
Crowther-Swanepoel D, Broderick P, Di Bernardo MC, et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 2010; 42: 132–6.
Di Bernardo MC, Crowther-Swanepoel D, Broderick P, et al. A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 2008; 40: 1204–10.
Kim T, Cui R, Jeon YJ, et al. Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5. Proc Natl Acad Sci USA 2014; 111: 4173–8.
Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feedforward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006; 103:18261–6.
Yada M, Hatakeyama S, Kamura T, et al. Phosphorylationdependent degradation of c-Myc is mediated by the F-box protein Fbw7. The EMBO J 2004; 23: 2116–25.
Collu GM, Hidalgo-Sastre A, Acar A, et al. Dishevelled limits Notch signalling through inhibition of CSL. Development 2012; 139: 4405–15.
Wang L, Brooks AN, Fan J, et al. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell 2016; 30: 750–63.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
